Literature DB >> 7295484

Modelling theophylline response in individual patients with chronic bronchitis.

B Whiting, A W Kelman, J Barclay, G J Addis.   

Abstract

1 In six patients with chronic bronchitis, serial changes in both ventilatory function and plasma theophylline concentrations were measured simultaneously for 8 h following 500 mg aminophylline intravenously. 2 Using empirical mathematical models which can integrate this data, parameters were estimated which can express response as a linear function of steady state plasma theophylline levels. 3 Taking Forced Vital Capacity (FVC) as the target response, the mean (+/- s.d.) increase in FVC was 0.06 +/- 0.02 l/micrograms ml-1, starting with pretreatment values in the range 1-21. 4 This analytical approach could be used to determine whether or not a patient with chronic bronchitis could obtain a satisfactory response to theophylline at plasma levels normally encountered in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7295484      PMCID: PMC1401901          DOI: 10.1111/j.1365-2125.1981.tb01254.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

Review 2.  The modelling of drug response.

Authors:  B Whiting; A W Kelman
Journal:  Clin Sci (Lond)       Date:  1980-11       Impact factor: 6.124

3.  Quantitative analysis of the disopyramide concentration-effect relationship.

Authors:  B Whiting; N H Holford; L B Sheiner
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

4.  Modeling of drug response in individual subjects.

Authors:  A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1980-04

5.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

6.  Theophylline-salbutamol interaction: bronchodilator response to salbutamol at maximally effective plasma theophylline concentrations.

Authors:  J Barclay; B Whiting; P A Meredith; G J Addis
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

  6 in total
  14 in total

Review 1.  Long acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease.

Authors:  M Cazzola; C F Donner; M G Matera
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Quantification of theophylline-induced eosinopenia and hypokalaemia in healthy volunteers.

Authors:  M C Braat; R E Jonkers; E H Bel; C J Van Boxtel
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

3.  The value of therapeutic drug monitoring to the practising physician--an hypothesis in need of testing.

Authors:  G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

Review 4.  Pharmacokinetic-pharmacodynamic modelling as applied to bronchial asthma.

Authors:  R P Koopmans; R E Jonkers; M C Braat; C J van Boxtel
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

5.  Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite.

Authors:  P A Meredith; A W Kelman; H L Elliott; J L Reid
Journal:  J Pharmacokinet Biopharm       Date:  1983-08

Review 6.  Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists.

Authors:  R Donnelly; H L Elliott; P A Meredith
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

7.  Self-poisoning with sustained-release aminophylline: secondary rise in serum theophylline concentration after charcoal haemoperfusion.

Authors:  A D Struthers; H L Elliott; G J Addis
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-05

8.  Plasma theophylline concentrations, six minute walking distances, and breathlessness in patients with chronic airflow obstruction.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-09

9.  Value of theophylline treatment in patients handicapped by chronic obstructive lung disease.

Authors:  S E McKay; C A Howie; A H Thomson; B Whiting; G J Addis
Journal:  Thorax       Date:  1993-03       Impact factor: 9.139

10.  Prediction of response to theophylline in chronic bronchitis.

Authors:  B Whiting; A W Kelman; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.